Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab + ibrutinib versus DRC as initial therapy for Waldenström's macroglobulinaemia
2019-001261-33Phase 2Unknown
- Sponsor
- University College London
- Start
- Jul 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in Waldenström macroglobulinemia (WM) comparing Rituximab + ibrutinib (RI) with DRC (dexamethasone + rituximab + cyclophosphamide) (2 arms). Primary endpoint: Preliminary efficacy (response) of rituximab + ibrutinib. Status: unknown.
02
Drugs
ibrutinibrituximabdexamethasonecyclophosphamide
03
Conditions
Waldenström macroglobulinemia (WM)
Beyond the preview
Go deeper on 2019-001261-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001261-33.